Cardio-vascular specialists have witnessed and actively participated in the revolutionary developments that have occurred
in their field of specialization over the last few years.
Cutting-edge technologies have led to dramatic improvements
in life-expectancy and quality of life. An open-mind and pioneering attitude are necessary when exploring new
frontiers to improve our patients’ health. However, naïve indiscriminate acceptance of novel mainstream therapies is not
always advisable and prudence is required in unearthing harmful, covert side effects. An objective review of contemporary
vascular research was performed and industrial bias was sifted out for a fresh prospective on how to promote primary
cardiovascular prevention with attainable lifestyle adjustments [1].
A comprehensive review of Pubmed, EMBASE
and Cochrane review databases was undertaken for articles relating to cardiovascular primary prevention and
statin side effects with the aim of harmonising their roles within contemporary clinic practice.
Particular attention was
paid to large-scale randomised controlled trials on contemporary cardiovascular pharmacotherapies and their specific
adverse effects on metabolic pathways which feature prominently in cardiovascular primary prevention and regenerative
programmes. There is a categorical lack of clinical evidence to support the use of statin therapy in primary prevention.
Not only is there a dearth of evidence for primary cardiovascular protection, there is ample evidence to show that
statins actually augment cardiovascular risk in women, patients with Diabetes Mellitus and in the young. Furthermore
statins are associated with triple the risk of coronary artery and aortic artery calcification
. Cardiovascular primary prevention
and regeneration programmes, through life style changes and abstaining from tobacco use have enhanced clinical
efficacy and quality of life over any pharmaceutical or other conventional intervention.
Read more
No comments:
Post a Comment